• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用超细微粒加工系统制备的有凹坑的艾塞那肽载 PLGA 微球的形成机制、体外与体内评价。

Formation Mechanism, In vitro and In vivo Evaluation of Dimpled Exenatide Loaded PLGA Microparticles Prepared by Ultra-Fine Particle Processing System.

机构信息

Guangdong University of Technology, Institute for Biomedical and Pharmaceutical Sciences, Guangzhou, 510006, China.

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.

出版信息

AAPS PharmSciTech. 2019 Jan 9;20(2):64. doi: 10.1208/s12249-018-1208-8.

DOI:10.1208/s12249-018-1208-8
PMID:30627822
Abstract

Spherical poly (D, L-lactic-co-glycolic acid) microparticles (PLGA-MPs) have long been investigated in order to achieve sustained delivery of proteins/peptides. However, the formation mechanism and release characteristics of the specific shape MPs were still unknown. This study aimed to develop a novel-dimpled exenatide-loaded PLGA-MPs (Exe-PLGA-MPs) using an ultra-fine particle processing system (UPPS) and investigate the formation mechanism and release characteristics. Exe-PLGA-MPs were prepared by UPPS and optimized based on their initial burst within the first 24 h and drug release profiles. Physicochemical properties of Exe-PLGA-MPs, including morphology, particle size, and structural integrity of Exe extracted from Exe-PLGA-MPs, were evaluated. Furthermore, pharmacokinetic studies of the optimal formulation were conducted in Sprague-Dawley (SD) rats to establish in vitro-in vivo correlations (IVIVC) of drug release. Exe-PLGA-MPs with dimpled shapes and uniform particle sizes achieved a high encapsulation efficiency (EE%, 91.50 ± 2.65%) and sustained drug release for 2 months in vitro with reduced initial burst (20.42 ± 1.64%). Moreover, the pharmacokinetic studies revealed that effective drug concentration could be maintained for 3 weeks following a single injection of dimpled Exe-PLGA-MPs with high IVIVC. Dimpled PLGA-MPs prepared using the UPPS technique could thus have great potential for sustained delivery of macromolecular proteins/peptides.

摘要

球形聚(D,L-乳酸-共-乙醇酸)微球(PLGA-MPs)长期以来一直被研究用于实现蛋白质/肽的持续递送。然而,特殊形状 MPs 的形成机制和释放特性仍然未知。本研究旨在使用超精细颗粒处理系统(UPPS)开发新型有凹坑的艾塞那肽负载 PLGA-MPs(Exe-PLGA-MPs),并研究其形成机制和释放特性。通过 UPPS 制备 Exe-PLGA-MPs,并根据其在最初 24 小时内的初始突释和药物释放曲线对其进行优化。对 Exe-PLGA-MPs 的理化性质进行评价,包括形态、粒径和从 Exe-PLGA-MPs 中提取的 Exe 的结构完整性。此外,在 Sprague-Dawley(SD)大鼠中进行最佳配方的药代动力学研究,以建立药物释放的体外-体内相关性(IVIVC)。具有凹坑形状和均匀粒径的 Exe-PLGA-MPs 实现了高包封效率(EE%,91.50±2.65%)和体外 2 个月的持续药物释放,初始突释减少(20.42±1.64%)。此外,药代动力学研究表明,通过单次注射凹坑 Exe-PLGA-MPs 可维持 3 周的有效药物浓度,具有较高的 IVIVC。因此,使用 UPPS 技术制备的凹坑 PLGA-MPs 可能具有用于持续递送大分子蛋白质/肽的巨大潜力。

相似文献

1
Formation Mechanism, In vitro and In vivo Evaluation of Dimpled Exenatide Loaded PLGA Microparticles Prepared by Ultra-Fine Particle Processing System.采用超细微粒加工系统制备的有凹坑的艾塞那肽载 PLGA 微球的形成机制、体外与体内评价。
AAPS PharmSciTech. 2019 Jan 9;20(2):64. doi: 10.1208/s12249-018-1208-8.
2
Comparative studies on exenatide-loaded poly (D,L-lactic-co-glycolic acid) microparticles prepared by a novel ultra-fine particle processing system and spray drying.通过新型超细颗粒加工系统和喷雾干燥制备的艾塞那肽负载聚(D,L-乳酸-乙醇酸共聚物)微粒的比较研究。
Colloids Surf B Biointerfaces. 2015 Aug 1;132:103-10. doi: 10.1016/j.colsurfb.2015.05.001. Epub 2015 May 11.
3
Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.艾塞那肽聚(DL-乳酸-乙醇酸共聚物)微球的制备、表征及药效学
Chem Pharm Bull (Tokyo). 2010 Nov;58(11):1474-9. doi: 10.1248/cpb.58.1474.
4
Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release characteristics.载有艾塞那肽的内部多孔聚(乳酸-共-乙醇酸)微球作为具有改善的释放特性的长效药物传递系统。
Drug Deliv. 2020 Nov 18;27(1):1667-1675. doi: 10.1080/10717544.2020.1850919.
5
In vivo evaluation of solid lipid microparticles and hybrid polymer-lipid microparticles for sustained delivery of leuprolide.体内评价固体脂质毫微粒和杂化聚合物-脂质毫微粒用于亮丙瑞林的缓释。
Eur J Pharm Biopharm. 2019 Sep;142:315-321. doi: 10.1016/j.ejpb.2019.07.010. Epub 2019 Jul 9.
6
Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats.载外啡肽-4 的壳聚糖-PLGA 微球的构建及性能评价对改善 2 型糖尿病大鼠种植体骨整合的作用。
Drug Deliv. 2022 Dec;29(1):548-560. doi: 10.1080/10717544.2022.2036873.
7
Preparation and in vivo pharmacokinetics of rhGH-loaded PLGA microspheres.载人生长激素 PLGA 微球的制备及体内药代动力学。
Pharm Dev Technol. 2019 Apr;24(4):395-401. doi: 10.1080/10837450.2018.1502316. Epub 2018 Nov 13.
8
Development of andrographolide loaded PLGA microspheres: optimization, characterization and in vitro-in vivo correlation.穿心莲内酯载药聚乳酸-羟基乙酸共聚物微球的研制:优化、表征及体内外相关性研究
Int J Pharm. 2014 Nov 20;475(1-2):475-84. doi: 10.1016/j.ijpharm.2014.09.016. Epub 2014 Sep 16.
9
Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy.利用 PLGA 纳米粒在酵母细胞壁颗粒系统中口服靶向递送艾塞那肽,以提高其降血糖效果。
Int J Pharm. 2021 May 15;601:120583. doi: 10.1016/j.ijpharm.2021.120583. Epub 2021 Apr 9.
10
Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability.制备具有高包封率和生物稳定性的均一大小的艾塞那肽载 PLGA 微球作为长效释放系统。
Colloids Surf B Biointerfaces. 2013 Dec 1;112:492-8. doi: 10.1016/j.colsurfb.2013.08.048. Epub 2013 Sep 7.

引用本文的文献

1
In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide).基于聚(丙交酯-乙交酯)的长效注射用药物产品的体外-体内相关性(IVIVC)研究
J Control Release. 2025 Jan 10;377:186-196. doi: 10.1016/j.jconrel.2024.11.021. Epub 2024 Nov 19.
2
Development of a UHPLC-MS/MS Method for the Determination of Moxidectin in Rat Plasma and Its Application in Pharmacokinetics.建立 UHPLC-MS/MS 法测定大鼠血浆中莫昔克丁的浓度及其药代动力学研究。
Molecules. 2024 Oct 10;29(20):4786. doi: 10.3390/molecules29204786.
3
Microstructure Formation and Characterization of Long-Acting Injectable Microspheres: The Gateway to Fully Controlled Drug Release Pattern.
长效注射微球的微观结构形成与表征:实现完全可控药物释放模式的途径。
Int J Nanomedicine. 2024 Feb 19;19:1571-1595. doi: 10.2147/IJN.S445269. eCollection 2024.
4
The Effect of Polymer Blends on the In Vitro Release/Degradation and Pharmacokinetics of Moxidectin-Loaded PLGA Microspheres.聚合物共混物对载米多君 PLGA 微球的体外释放/降解和药代动力学的影响。
Int J Mol Sci. 2023 Sep 29;24(19):14729. doi: 10.3390/ijms241914729.
5
Characterization of Pharmaceutical Tablets by X-ray Tomography.通过X射线断层扫描对药物片剂进行表征。
Pharmaceuticals (Basel). 2023 May 11;16(5):733. doi: 10.3390/ph16050733.
6
Fighting type 2 diabetes: Formulation strategies for peptide-based therapeutics.对抗2型糖尿病:基于肽的治疗药物的配方策略。
Acta Pharm Sin B. 2022 Feb;12(2):621-636. doi: 10.1016/j.apsb.2021.08.003. Epub 2021 Aug 10.
7
Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era.基于膜破坏肽/肽模拟物的疗法:在耐药时代对抗细菌和癌症的有前景的系统。
Acta Pharm Sin B. 2021 Sep;11(9):2609-2644. doi: 10.1016/j.apsb.2021.07.014. Epub 2021 Jul 21.
8
PLGA/PLA-Based Long-Acting Injectable Depot Microspheres in Clinical Use: Production and Characterization Overview for Protein/Peptide Delivery.PLGA/PLA 基长效注射储库微球的临床应用:蛋白/肽给药的生产和特性概述。
Int J Mol Sci. 2021 Aug 18;22(16):8884. doi: 10.3390/ijms22168884.
9
Cartilage Extracellular Matrix Scaffold With Kartogenin-Encapsulated PLGA Microspheres for Cartilage Regeneration.含卡托金包裹的聚乳酸-羟基乙酸共聚物微球的软骨细胞外基质支架用于软骨再生
Front Bioeng Biotechnol. 2020 Dec 9;8:600103. doi: 10.3389/fbioe.2020.600103. eCollection 2020.
10
Release mechanisms of bovine serum albumin loaded-PLGA microspheres prepared by ultra-fine particle processing system.通过超微颗粒加工系统制备的载牛血清白蛋白聚乳酸-羟基乙酸共聚物微球的释放机制
Drug Deliv Transl Res. 2020 Oct;10(5):1267-1277. doi: 10.1007/s13346-020-00774-9.